Achieving Broad Participation in Meaningful Clinical Research at the Point of Care
Public Meeting
June 14, 2022

Meeting Objective: The costs of clinical trials are high and rising, resulting in slow innovation in many areas and limiting the types of sites that can run clinical trials. The Coalition for Advancing Clinical Trials at the Point of Care is convening this meeting to explore the barriers to broader clinical trial participation by clinicians at the point of care as well as new opportunities to overcome these barriers. Enabling more meaningful clinical research at the point of care will help close major gaps in clinical trial evidence generation, improve patient care, and move us towards a learning health system.

2:00 p.m. Welcome

2:10 p.m. Keynote and Discussion

2:35 p.m. Session 1: Why This Matters for Health Systems
Objective: This session will feature representatives from health systems leadership to discuss their interest in generating more practically relevant evidence faster. Panelists will share their experiences working to close evidence gaps and improve care quality.

3:10 p.m. Session 2: Promising Areas for Progress
Objective: This forward-looking session will provide an overview of two areas of work planned by The Coalition for Advancing Clinical Trials at the Point of Care for 2022 and highlight promising priority therapeutic disease areas for implementation of point-of-care research.

3:55 p.m. Session 3: Utilizing Digital Tools to Increase Efficiency
Objective: Panelists in this session will explore how progress can be accelerated in digital tool validation and adoption. Participants will highlight promising existing examples of tools, such as mCODE, consider how such tools might be applied to clinical trials across product and disease classes, and discuss opportunities to improve data linkage and data interoperability by leveraging existing standards to collect higher quality data on outcomes for patients.

4:30 p.m. Session 4: Policy Considerations for Broadening Participation
Objective: Participants in this session will consider regulatory and reimbursement strategies for broadening clinician participation in clinical trials and clinical trial representativeness. Discussion will include approaches for incentivizing patient and provider participation, training requirements, potential liability concerns, areas for better stakeholder coordination, and where funding might be needed for new infrastructure.

5:10 p.m. Closing Remarks and Adjournment